{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:50:38Z","timestamp":1740142238022,"version":"3.37.3"},"reference-count":62,"publisher":"Bentham Science Publishers Ltd.","issue":"16","funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The emergence of the pathogen Candida auris is a real concern worldwide, especially\ndue to its multidrug resistance profile, besides the difficulties in establishing the correct identification\nby conventional laboratory methods and its capacity of causing outbreaks in healthcare settings.\nThe limited arsenal of available antifungal drugs, coupled with the lack of momentum for the development\nof new reagents, represent a challenge in the management of such a pathogen. In this\nperspective, we have focused on discussing new, promising treatment options for C. auris infections.\nThese novel drugs include an antifungal agent already approved for medical use in the United\nStates of America, compounds that are already in clinical trials and those with potential for repurposing\nuse against this important fungal pathogen.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026622666220520153748","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T05:16:26Z","timestamp":1653628586000},"page":"1297-1305","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prospective Medicines against the Widespread, Emergent, and Multidrugresistant\nOpportunistic Fungal Pathogen Candida auris: A Breath of\nHope"],"prefix":"10.2174","volume":"22","author":[{"given":"L\u00edvia de Souza","family":"Ramos","sequence":"first","affiliation":[{"name":"Laborat\u00f3rio de Estudos Avan\u00e7ados de Microrganismos Emergentes e Resistentes, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de G\u00f3es, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Nunes","family":"Silva","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Estudos Avan\u00e7ados de Microrganismos Emergentes e Resistentes, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de G\u00f3es, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tha\u00eds Pereira","family":"de Mello","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Estudos Avan\u00e7ados de Microrganismos Emergentes e Resistentes, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de G\u00f3es, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helo\u00edsa Freire","family":"Frota","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Estudos Avan\u00e7ados de Microrganismos Emergentes e Resistentes, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de G\u00f3es, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil"},{"name":"Programa de P\u00f3s-Gradua\u00e7\u00e3o em Bioqu\u00edmica, Instituto de Qu\u00edmica, Universidade Federal do Rio de Janeiro, Rio de\nJaneiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta Helena","family":"Branquinha","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Estudos Avan\u00e7ados de Microrganismos Emergentes e Resistentes, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de G\u00f3es, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil"},{"name":"Rede Micologia RJ - FAPERJ, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 Luis Souza","family":"dos Santos","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Estudos Avan\u00e7ados de Microrganismos Emergentes e Resistentes, Departamento de Microbiologia Geral, Instituto de Microbiologia Paulo de G\u00f3es, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil"},{"name":"Programa de P\u00f3s-Gradua\u00e7\u00e3o em Bioqu\u00edmica, Instituto de Qu\u00edmica, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil"},{"name":"Rede Micologia RJ - FAPERJ, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/21501203.2019.1614106","volume":"10","author":"Wu B.","year":"2019","unstructured":"Wu B.; Hussain M.; Zhang W.; Stadler M.; Liu X.; Xiang M.; Current insights into fungal species diversity and perspective on naming the environmental DNA sequences of fungi. Mycology 2019,10(3),127-140","journal-title":"Mycology"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.2174\/1568026617666170105145227","volume":"17","author":"de Mello T.P.","year":"2017","unstructured":"de Mello T.P.; de Souza Ramos L.; Braga-Silva L.A.; Branquinha M.H.; Santos A.L.S.; Fungal biofilm - a real obstacle against an efficient therapy: Lessons from Candida. Curr Top Med Chem 2017,17(17),1987-2004","journal-title":"Curr Top Med Chem"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1053\/j.semdp.2019.04.010","volume":"36","author":"Lockhart S.R.","year":"2019","unstructured":"Lockhart S.R.; Guarner J.; Emerging and reemerging fungal infections. Semin Diagn Pathol 2019,36(3),177-181","journal-title":"Semin Diagn Pathol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/jof3040057","volume":"3","author":"Bongomin F.","year":"2017","unstructured":"Bongomin F.; Gago S.; Oladele R.O.; Denning D.W.; Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel) 2017,3(4),57","journal-title":"J Fungi (Basel)"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"165rv13","DOI":"10.1126\/scitranslmed.3004404","volume":"4","author":"Brown G.D.","year":"2012","unstructured":"Brown G.D.; Denning D.W.; Gow N.A.R.; Levitz S.M.; Netea M.G.; White T.C.; Hidden killers: Human fungal infections. Sci Transl Med 2012,4(165),165rv13","journal-title":"Sci Transl Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e0007964","DOI":"10.1371\/journal.pntd.0007964","volume":"14","author":"Rodrigues M.L.","year":"2020","unstructured":"Rodrigues M.L.; Nosanchuk J.D.; Fungal diseases as neglected pathogens: A wake-up call to public health officials. PLoS Negl Trop Dis 2020,14(2),e0007964","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.2174\/156802662022200917110102","volume":"20","author":"Silva L.N.","year":"2020","unstructured":"Silva L.N.; de Mello T.P.; de Souza Ramos L.; Branquinha M.H.; Roudbary M.; Santos A.L.S.; Fungal infections in COVID-19-positive patients: A lack of optimal treatment options. Curr Top Med Chem 2020,20(22),1951-1957","journal-title":"Curr Top Med Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3390\/jof7110921","volume":"7","author":"Casalini G.","year":"2021","unstructured":"Casalini G.; Giacomelli A.; Ridolfo A.; Gervasoni C.; Antinori S.; Invasive fungal infections complicating COVID-19: A narrative review. J Fungi (Basel) 2021,7(11),921","journal-title":"J Fungi (Basel)"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2017.00036","volume":"8","author":"Scorzoni L.","year":"2017","unstructured":"Scorzoni L.; de Paula e Silva, A.C.A.; Marcos, C.M.; Assato, P.A.; de Melo, W.C.M.A.; de Oliveira, H.C.; Costa-Orlandi, C.B.; Mendes-Giannini, M.J.S.; Fusco-Almeida, A.M. Antifungal therapy: New advances in the understanding and treatment of mycosis. Front Microbiol 2017,8,1-23","journal-title":"Front Microbiol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1086\/421946","volume":"39","author":"Wisplinghoff H.","year":"2004","unstructured":"Wisplinghoff H.; Bischoff T.; Tallent S.M.; Seifert H.; Wenzel R.P.; Edmond M.B.; Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004,39(3),309-317","journal-title":"Clin Infect Dis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1099\/jmm.0.045054-0","volume":"62","author":"Sardi J.C.O.","year":"2013","unstructured":"Sardi J.C.O.; Scorzoni L.; Bernardi T.; Fusco-Almeida A.M.; Mendes Giannini M.J.S.; Candida species: Current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol 2013,62(Pt 1),10-24","journal-title":"J Med Microbiol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3201\/eid2302.161486","volume":"23","author":"Ben-Ami R.","year":"2017","unstructured":"Ben-Ami R.; Berman J.; Novikov A.; Bash E.; Shachor-Meyouhas Y.; Zakin S.; Maor Y.; Tarabia J.; Schechner V.; Adler A.; Finn T.; Multidrug-resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis 2017,23(1),195-203","journal-title":"Emerg Infect Dis"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.3390\/ijms22094470","volume":"22","author":"\u010cern\u00e1kov\u00e1 L.","year":"2021","unstructured":"\u010cern\u00e1kov\u00e1 L.; Roudbary M.; Br\u00e1s S.; Tafaj S.; Rodrigues C.F.; Candida auris: A quick review on identification, current treatments, and challenges. Int J Mol Sci 2021,22(9),4470","journal-title":"Int J Mol Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1038\/s41467-018-07779-6","volume":"9","author":"Mu\u00f1oz J.F.","year":"2018","unstructured":"Mu\u00f1oz J.F.; Gade L.; Chow N.A.; Loparev V.N.; Juieng P.; Berkow E.L.; Farrer R.A.; Litvintseva A.P.; Cuomo C.A.; Genomic insights into multidrug-resistance, mating and virulence in Candida auris and related emerging species. Nat Commun 2018,9(1),5346","journal-title":"Nat Commun"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.2174\/1568026619666191025152412","volume":"19","author":"Silva L.N.","year":"2019","unstructured":"Silva L.N.; de Mello T.P.; de Souza Ramos L.; Branquinha M.H.; Santos A.L.S.; New and promising chemotherapeutics for emerging infections involving drug-resistant non-albicans Candida species. Curr Top Med Chem 2019,19(28),2527-2553","journal-title":"Curr Top Med Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"e00578","DOI":"10.1002\/mbo3.578","volume":"7","author":"Osei Sekyere J.","year":"2018","unstructured":"Osei Sekyere J.; Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. MicrobiologyOpen 2018,7(4),e00578","journal-title":"MicrobiologyOpen"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/cid\/ciw691","volume":"64","author":"Lockhart S.R.","year":"2017","unstructured":"Lockhart S.R.; Etienne K.A.; Vallabhaneni S.; Farooqi J.; Chowdhary A.; Govender N.P.; Colombo A.L.; Calvo B.; Cuomo C.A.; Desjardins C.A.; Berkow E.L.; Castanheira M.; Magobo R.E.; Jabeen K.; Asghar R.J.; Meis J.F.; Jackson B.; Chiller T.; Litvintseva A.P.; Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis 2017,64(2),134-140","journal-title":"Clin Infect Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.mib.2018.02.005","volume":"45","author":"Revie N.M.","year":"2018","unstructured":"Revie N.M.; Iyer K.R.; Robbins N.; Cowen L.E.; Antifungal drug resistance: evolution, mechanisms and impact. Curr Opin Microbiol 2018,45,70-76","journal-title":"Curr Opin Microbiol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/jac\/dkx480","volume":"73","author":"Chowdhary A.","year":"2018","unstructured":"Chowdhary A.; Prakash A.; Sharma C.; Kordalewska M.; Kumar A.; Sarma S.; Tarai B.; Singh A.; Upadhyaya G.; Upadhyay S.; Yadav P.; Singh P.K.; Khillan V.; Sachdeva N.; Perlin D.S.; Meis J.F.; A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: Role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother 2018,73(4),891-899","journal-title":"J Antimicrob Chemother"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"e00057","DOI":"10.1128\/AAC.00057-19","volume":"63","author":"Rybak J.M.","year":"2019","unstructured":"Rybak J.M.; Doorley L.A.; Nishimoto A.T.; Barker K.S.; Palmer G.E.; Rogers P.D.; Abrogation of triazole resistance upon deletion of CDR1 in a clinical isolate of Candida auris. Antimicrob Agents Chemother 2019,63(4),e00057-e19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3390\/jof6040215","volume":"6","author":"Silva L.N.","year":"2020","unstructured":"Silva L.N.; Ramos L.S.; Oliveira S.S.C.; Magalh\u00e3es L.B.; Squizani E.D.; Kmetzsch L.; Vainstein M.H.; Branquinha M.H.; Santos A.L.S.; Insights into the multi-azole resistance profile in Candida haemulonii species complex. J Fungi (Basel) 2020,6(4),215","journal-title":"J Fungi (Basel)"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1021\/acsinfecdis.0c00117","volume":"6","author":"Silva L.N.","year":"2020","unstructured":"Silva L.N.; Oliveira S.S.C.; Magalh\u00e3es L.B.; Andrade Neto V.V.; Torres-Santos E.C.; Carvalho M.D.C.; Pereira M.D.; Branquinha M.H.; Santos A.L.S.; Unmasking the amphotericin B resistance mechanisms in Candida haemulonii species complex. ACS Infect Dis 2020,6(5),1273-1282","journal-title":"ACS Infect Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/jof6040321","volume":"6","author":"Carolus H.","year":"2020","unstructured":"Carolus H.; Pierson S.; Lagrou K.; Van Dijck P.; Amphotericin B and other polyenes-discovery, clinical use, mode of action and drug resistance. J Fungi (Basel) 2020,6(4),321","journal-title":"J Fungi (Basel)"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1128\/AAC.47.8.2404-2412.2003","volume":"47","author":"Sanglard D.","year":"2003","unstructured":"Sanglard D.; Ischer F.; Parkinson T.; Falconer D.; Bille J.; Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob Agents Chemother 2003,47(8),2404-2412","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01900-18","volume":"63","author":"Ahmad S.","year":"2019","unstructured":"Ahmad S.; Joseph L.; Parker J.E.; Asadzadeh M.; Kelly S.L.; Meis J.F.; Khan Z.; ERG6 and ERG2 are major targets conferring reduced susceptibility to Amphotericin B in clinical Candida glabrata isolates in Kuwait. Antimicrob Agents Chemother 2019,63(2),1-12","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"e1001692","DOI":"10.1371\/journal.pbio.1001692","volume":"11","author":"Vincent B.M.","year":"2013","unstructured":"Vincent B.M.; Lancaster A.K.; Scherz-Shouval R.; Whitesell L.; Lindquist S.; Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol 2013,11(10),e1001692","journal-title":"PLoS Biol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2174\/156802661907190531093808","volume":"19","author":"Silva L.N.","year":"2019","unstructured":"Silva L.N.; de Mello T.P.; de Souza Ramos L.; Branquinha M.H.; Santos A.L.S.; Current challenges and updates on the therapy of fungal infections. Curr Top Med Chem 2019,19(7),495-499","journal-title":"Curr Top Med Chem"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1146\/annurev-micro-030117-020345","volume":"71","author":"Robbins N.","year":"2017","unstructured":"Robbins N.; Caplan T.; Cowen L.E.; Molecular evolution of antifungal drug resistance. Annu Rev Microbiol 2017,71(1),753-775","journal-title":"Annu Rev Microbiol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"S445","DOI":"10.1093\/infdis\/jix131","volume":"216","author":"Arendrup M.C.","year":"2017","unstructured":"Arendrup M.C.; Patterson T.F.; Multidrug-resistant Candida: Epidemiology, molecular mechanisms, and treatment. J Infect Dis 2017,216(Suppl. 3),S445-S451","journal-title":"J Infect Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00238-18","volume":"62","author":"Kordalewska M.","year":"2018","unstructured":"Kordalewska M.; Lee A.; Park S.; Berrio I.; Chowdhary A.; Zhao Y.; Perlin D.S.; Understanding echinocandin resistance in the emerging pathogen Candida auris. Antimicrob Agents Chemother 2018,62(6),1-9","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41426-018-0045-x","volume":"7","author":"Rhodes J.","year":"2018","unstructured":"Rhodes J.; Abdolrasouli A.; Farrer R.A.; Cuomo C.A.; Aanensen D.M.; Armstrong-James D.; Fisher M.C.; Schelenz S.; Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris. Emerg Microbes Infect 2018,7(1),43-43","journal-title":"Emerg Microbes Infect"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/cid\/civ571","volume":"61","author":"Miceli M.H.","year":"2015","unstructured":"Miceli M.H.; Kauffman C.A.; Isavuconazole: A new broad-spectrum triazole antifungal agent. Clin Infect Dis 2015,61(10),1558-1565","journal-title":"Clin Infect Dis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3390\/antibiotics9090539","volume":"9","author":"Ghannoum M.","year":"2020","unstructured":"Ghannoum M.; Arendrup M.C.; Chaturvedi V.P.; Lockhart S.R.; McCormick T.S.; Chaturvedi S.; Berkow E.L.; Juneja D.; Tarai B.; Azie N.; Angulo D.; Walsh T.J.; Ibrexafungerp: A novel oral triterpenoid antifungal in development for the treatment of Candida auris infections. Antibiotics (Basel) 2020,9(9),539","journal-title":"Antibiotics (Basel)"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"e02396","DOI":"10.1128\/AAC.02396-16","volume":"61","author":"Larkin E.","year":"2017","unstructured":"Larkin E.; Hager C.; Chandra J.; Mukherjee P.K.; Retuerto M.; Salem I.; Long L.; Isham N.; Kovanda L.; Borroto-Esoda K.; Wring S.; Angulo D.; Ghannoum M.; The emerging pathogen Candida auris: Growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. Antimicrob Agents Chemother 2017,61(5),e02396-e16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"e02136","DOI":"10.1128\/AAC.02136-19","volume":"64","author":"Arendrup M.C.","year":"2020","unstructured":"Arendrup M.C.; J\u00f8rgensen K.M.; Hare R.K.; Chowdhary A.; In vitro activity of Ibrexafungerp (SCY-078) against Candida auris isolates as determined by EUCAST methodology and comparison with activity against C. albicans and C. glabrata and with the activities of six comparator agents. Antimicrob Agents Chemother 2020,64(3),e02136-e19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"105922","DOI":"10.1016\/j.ijantimicag.2020.105922","volume":"55","author":"Zhu Y.C.","year":"2020","unstructured":"Zhu Y.C.; Barat S.A.; Borroto-Esoda K.; Angulo D.; Chaturvedi S.; Chaturvedi V.; Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor). Int J Antimicrob Agents 2020,55(4),105922","journal-title":"Int J Antimicrob Agents"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"e02694","DOI":"10.1128\/AAC.02694-20","volume":"65","author":"Wiederhold N.P.","year":"2021","unstructured":"Wiederhold N.P.; Najvar L.K.; Olivo M.; Morris K.N.; Patterson H.P.; Catano G.; Patterson T.F.; Ibrexafungerp demonstrates in vitro activity against fluconazole-resistant Candida auris and in vivo efficacy with delayed initiation of therapy in an experimental model of invasive candidiasis. Antimicrob Agents Chemother 2021,65(6),e02694-e20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1080\/17512433.2021.1949285","volume":"14","author":"Giacobbe D.R.","year":"2021","unstructured":"Giacobbe D.R.; Magnasco L.; Sepulcri C.; Mikulska M.; Koehler P.; Cornely O.A.; Bassetti M.; Recent advances and future perspectives in the pharmacological treatment of Candida auris infections. Expert Rev Clin Pharmacol 2021,14(10),1205-1220","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","volume":"81","author":"Hoenigl M.","year":"2021","unstructured":"Hoenigl M.; Sprute R.; Egger M.; Arastehfar A.; Cornely O.A.; Krause R.; Lass-Fl\u00f6rl C.; Prattes J.; Spec A.; Thompson G.R.; Wiederhold N.; Jenks J.D.; The antifungal pipeline: Fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs 2021,81(15),1703-1729","journal-title":"Drugs"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.diagmicrobio.2017.10.021","volume":"90","author":"Berkow E.L.","year":"2018","unstructured":"Berkow E.L.; Lockhart S.R.; Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris. Diagn Microbiol Infect Dis 2018,90(3),196-197","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"e02438","DOI":"10.1128\/AAC.02438-19","volume":"64","author":"Helleberg M.","year":"2020","unstructured":"Helleberg M.; J\u00f8rgensen K.M.; Hare R.K.; Datcu R.; Chowdhary A.; Arendrup M.C.; Rezafungin in vitro activity against contemporary Nordic clinical Candida isolates and Candida auris determined by the EUCAST Reference Method. Antimicrob Agents Chemother 2020,64(4),e02438-e19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/jac\/dkz390","volume":"74","author":"T\u00f3th Z.","year":"2019","unstructured":"T\u00f3th Z.; Forg\u00e1cs L.; Locke J.B.; Kardos G.; Nagy F.; Kov\u00e1cs R.; Szekely A.; Borman A.M.; Majoros L.; In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae. J Antimicrob Chemother 2019,74(12),3505-3510","journal-title":"J Antimicrob Chemother"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1093\/jac\/dky153","volume":"73","author":"Hager C.L.","year":"2018","unstructured":"Hager C.L.; Larkin E.L.; Long L.A.; Ghannoum M.A.; Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J Antimicrob Chemother 2018,73(8),2085-2088","journal-title":"J Antimicrob Chemother"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"e01124","DOI":"10.1128\/AAC.01124-20","volume":"64","author":"Zhu Y.","year":"2020","unstructured":"Zhu Y.; Kilburn S.; Kapoor M.; Chaturvedi S.; Shaw K.J.; Chaturvedi V.; In vitro activity of Manogepix against multidrug-resistant and panresistant Candida auris from the New York outbreak. Antimicrob Agents Chemother 2020,64(11),e01124-e20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"e01225","DOI":"10.1128\/AAC.01225-18","volume":"62","author":"Arendrup M.C.","year":"2018","unstructured":"Arendrup M.C.; Chowdhary A.; Astvad K.M.T.; J\u00f8rgensen K.M.; APX001A in vitro activity against contemporary blood isolates and Candida auris determined by the EUCAST reference method. Antimicrob Agents Chemother 2018,62(10),e01225-e18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"e00656","DOI":"10.1128\/AAC.00656-20","volume":"64","author":"Arendrup M.C.","year":"2020","unstructured":"Arendrup M.C.; Chowdhary A.; J\u00f8rgensen K.M.; Meletiadis J.; Manogepix (APX001A) in vitro activity against Candida auris: Head-to-head comparison of EUCAST and CLSI MICs. Antimicrob Agents Chemother 2020,64(10),e00656-e20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1093\/jac\/dky302","volume":"73","author":"Berkow E.L.","year":"2018","unstructured":"Berkow E.L.; Lockhart S.R.; Activity of novel antifungal compound APX001A against a large collection of Candida auris. J Antimicrob Chemother 2018,73(11),3060-3062","journal-title":"J Antimicrob Chemother"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"e02319","DOI":"10.1128\/AAC.02319-17","volume":"62","author":"Hager C.L.","year":"2018","unstructured":"Hager C.L.; Larkin E.L.; Long L.; Zohra Abidi F.; Shaw K.J.; Ghannoum M.A.; In vitro and in vivo evaluation of the antifungal activity of APX001A\/APX001 against Candida auris. Antimicrob Agents Chemother 2018,62(3),e02319-e17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"e01120","DOI":"10.1128\/AAC.01120-19","volume":"63","author":"Wiederhold N.P.","year":"2019","unstructured":"Wiederhold N.P.; Najvar L.K.; Shaw K.J.; Jaramillo R.; Patterson H.; Olivo M.; Catano G.; Patterson T.F.; Efficacy of delayed therapy with Fosmanogepix (APX001) in a murine model of Candida auris invasive candidiasis. Antimicrob Agents Chemother 2019,63(11),e01120-e19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"597931","DOI":"10.3389\/fcimb.2020.597931","volume":"10","author":"Wall G.","year":"2020","unstructured":"Wall G.; Chen E.; Hull M.V.; Lopez-Ribot J.L.; Screening the CALIBR ReFRAME Library in search for inhibitors of Candida auris biofilm formation. Front Cell Infect Microbiol 2020,10,597931","journal-title":"Front Cell Infect Microbiol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrd2030","volume":"5","author":"Ghofrani H.A.","year":"2006","unstructured":"Ghofrani H.A.; Osterloh I.H.; Grimminger F.; Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006,5(8),689-702","journal-title":"Nat Rev Drug Discov"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/534314a","volume":"534","author":"Nosengo N.","year":"2016","unstructured":"Nosengo N.; Can you teach old drugs new tricks? Nature 2016,534(7607),314-316","journal-title":"Nature"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"Ashburn T.T.","year":"2004","unstructured":"Ashburn T.T.; Thor K.B.; Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004,3(8),673-683","journal-title":"Nat Rev Drug Discov"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s10822-019-00230-y","volume":"33","author":"Bustamante C.","year":"2019","unstructured":"Bustamante C.; Ochoa R.; Asela C.; Muskus C.; Repurposing of known drugs for leishmaniasis treatment using bioinformatic predictions, in vitro validations and pharmacokinetic simulations. J Comput Aided Mol Des 2019,33(9),845-854","journal-title":"J Comput Aided Mol Des"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"106049","DOI":"10.1016\/j.ijantimicag.2020.106049","volume":"56","author":"Barreto T.L.","year":"2020","unstructured":"Barreto T.L.; Rossato L.; de Freitas A.L.D.; Meis J.F.; Lopes L.B.; Colombo A.L.; Ishida K.; Miltefosine as an alternative strategy in the treatment of the emerging fungus Candida auris. Int J Antimicrob Agents 2020,56(2),106049","journal-title":"Int J Antimicrob Agents"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"e02063","DOI":"10.1128\/AAC.02063-19","volume":"64","author":"Wu Y.","year":"2020","unstructured":"Wu Y.; Totten M.; Memon W.; Ying C.; Zhang S.X.; In vitro antifungal susceptibility of the emerging multidrug-reistant pathogen Candida auris to miltefosine alone and in combination with amphotericin B. Antimicrob Agents Chemother 2020,64(2),e02063-e19","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"6996","DOI":"10.1128\/AAC.03212-14","volume":"58","author":"Imbert S.","year":"2014","unstructured":"Imbert S.; Palous M.; Meyer I.; Dannaoui E.; Mazier D.; Datry A.; Fekkar A.; In vitro combination of voriconazole and miltefosine against clinically relevant molds. Antimicrob Agents Chemother 2014,58(11),6996-6998","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1099\/jmm.0.000019","volume":"64","author":"Compain F.","year":"2015","unstructured":"Compain F.; Botterel F.; Sitterl\u00e9 E.; Paugam A.; Bougnoux M.E.; Dannaoui E.; In vitro activity of miltefosine in combination with voriconazole or amphotericin B against clinical isolates of Scedosporium spp. J Med Microbiol 2015,64(Pt 3),309-311","journal-title":"J Med Microbiol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"116293","DOI":"10.1016\/j.bmc.2021.116293","volume":"44","author":"Zhou J.","year":"2021","unstructured":"Zhou J.; Li J.; Cheong I.; Liu N.N.; Wang H.; Evaluation of artemisinin derivative artemether as a fluconazole potentiator through inhibition of Pdr5. Bioorg Med Chem 2021,44,116293","journal-title":"Bioorg Med Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"e01305","DOI":"10.1128\/AAC.01305-20","volume":"65","author":"Cheng Y.S.","year":"2021","unstructured":"Cheng Y.S.; Roma J.S.; Shen M.; Mota Fernandes C.; Tsang P.S.; Forbes H.E.; Boshoff H.; Lazzarini C.; Del Poeta M.; Zheng W.; Williamson P.R.; Identification of antifungal compounds against multidrug-resistant Candida auris utilizing a High-Throughput Drug-Repurposing Screen. Antimicrob Agents Chemother 2021,65(4),e01305-e01320","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/jam.14490","volume":"128","author":"Gowri M.","year":"2020","unstructured":"Gowri M.; Jayashree B.; Jeyakanthan J.; Girija E.K.; Sertraline as a promising antifungal agent: Inhibition of growth and biofilm of Candida auris with special focus on the mechanism of action in vitro. J Appl Microbiol 2020,128(2),426-437","journal-title":"J Appl Microbiol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1080\/21505594.2020.1838741","volume":"11","author":"Eldesouky H.E.","year":"2020","unstructured":"Eldesouky H.E.; Lanman N.A.; Hazbun T.R.; Seleem M.N.; Aprepitant, an antiemetic agent, interferes with metal ion homeostasis of Candida auris and displays potent synergistic interactions with azole drugs. Virulence 2020,11(1),1466-1481","journal-title":"Virulence"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026622666220520153748","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/205093\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1568026622666220520153748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T18:53:38Z","timestamp":1691866418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/205093\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":62,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026622666220520153748","relation":{},"ISSN":["1568-0266"],"issn-type":[{"type":"print","value":"1568-0266"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-03-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}